Product Development

"I am most proud of the ground-breaking progress our company has made in developing our revolutionary ApoA-I technology. This will have a positive impact on the lives of patients with cardiovascular disease."
Dr. Jan Johansson, Senior VP Medical Affairs

Building a World Class Pipeline

Resverlogix is a product-driven drug development company with multiple programs focused on the most grievous diseases.

NexVas™ Plaque Regression (NexVas PR) is a technology platform for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases.

NexVas™ Vascular Inflammation (NexVas VI) is a discovery stage technology for the development of drugs that target molecular markers of inflammation.

NexVas™ Alzheimer's Disease (NexVas AD) is a discovery stage technology for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque (AD).

ReVas™ is a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases.

TGF-β Shield™ is a research stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions.